ArticleDementia and geriatric cognitive disorders2026
Differentiating Behavioural Presentations of Biomarker-Confirmed Alzheimer's Disease from Frontotemporal Lobar Degeneration Using the Addenbrooke's Cognitive Examination-III.
Article in Dementia and geriatric cognitive disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDifferentiating frontotemporal lobar degeneration (FTLD) from Alzheimer's disease (AD), particularly when presenting with overlapping behavioural symptoms, remains clinically challenging. This study assessed the utility of Addenbrooke's Cognitive Examination-III (ACE-III)-derived ratios in distinguishing these conditions.
methodsA retrospective cohort of 115 patients (n = 52 biomarker-confirmed AD, n = 63 FTLD) with overlapping behavioural symptoms was analysed. ACE-III scores and behavioural profiles were examined, and novel ratios were tested.
resultsThe novel Phonemic Fluency/Orientation-Memory (PFOM) ratio outperformed existing ACE-III metrics, achieving an area under the curve of 0.85 (sensitivity 84.1%, specificity 73.1%) for differentiating FTLD from AD. Notably, longer symptom duration in AD, but not in FTLD, was associated with worsening frontal and cognitive symptoms. Patients with AD were significantly older than those with FTLD.
conclusionThese novel ratios showed robust diagnostic performance, regardless of disease duration, and better reflect FTLDs cognitive profile. They may offer improved clinical utility over traditional ACE-III measures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.